Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury

Taku Fujii, Hideaki Obara, Kentaro Matsubara, Naoki Fujimura, Hiroshi Yagi, Taizo Hibi, Yuta Abe, Minoru Kitago, Masahiro Shinoda, Osamu Itano, Minoru Tanabe, Yohei Masugi, Michiie Sakamoto, Yuko Kitagawa

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Background Cilostazol is a type III phosphodiesterase inhibitor used to treat the symptoms of intermittent claudication. Recent studies have shown that cilostazol decreases ischemia/reperfusion (I/R) injury in several organs. Materials and methods We evaluated the effects of cilostazol in a rat model of liver I/R injury. Thirty male Wistar rats with liver I/R injury were divided into a cilostazol or saline (control) group (n = 15 each). Each rat was orally administered cilostazol or saline for 3 d before I/R injury. Liver I/R injury was induced via 1 h of warm ischemia of the median and left lateral liver lobes, followed by 3 h of reperfusion. The rats were then euthanized. Serum aspartate aminotransferase, alanine aminotransferase, interleukin (IL)-1β, IL-6, and tumor necrosis factor-α levels were measured. The Mann–Whitney U test was used to compare the differences between the treatment groups. Histologic examination was performed on the liver tissues. We also conducted a survival study to confirm the effect of cilostazol on the mortality rate in rats. For the survival study, a liver I/R injury model with an ischemia time of 1.5 h was used, and the rats were observed for 1 wk. Results Serum aspartate aminotransferase, alanine aminotransferase, IL-1β, and IL-6 levels were significantly lower in the cilostazol group than in the saline group. Treatment with cilostazol significantly improved pathological findings associated with liver I/R injury and increased survival rate compared to that in controls. Conclusions Cilostazol reduced mortality and alleviated the effects of liver I/R injury in Wistar rats.

Original languageEnglish
Pages (from-to)207-214
Number of pages8
JournalJournal of Surgical Research
Publication statusPublished - 2017 Jun 1


  • Alanine aminotransferase
  • Aspartate aminotransferase
  • Cilostazol
  • Hepatocyte injury
  • Partial ischemia/reperfusion injury
  • Phosphodiesterase III inhibitor

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury'. Together they form a unique fingerprint.

Cite this